AlphAIAlphAI — Financial news for AI agents
benzinga.com$IONS

Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.

Original reporting
benzinga.com
Published Sep 22, 2026, 2:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 3:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$IONS
Bullish
medium confidence
Mentioned
$IONS · $VCYT · $BEAM · $SCTX · $TXG · $ARKG
Relevance
4/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$IONSBullishLow
01

Why it matters

The trades provide fresh capital to selected companies and illustrate ARKG's active management style versus broader biotech ETFs.

02

Market read

The disclosed trades may influence short‑term price action in the highlighted biotech stocks and affect ARKG's NAV composition.

03

What to watch

Liquidity constraints of small‑cap biotech may limit price gains despite ETF buying.

Relevance 4/10Novelty 3/10Timing: Monday trade disclosed today

Background

Cathie Wood's ARK Genomic Revolution ETF disclosed recent portfolio changes, adding and trimming biotech positions.

Company-level read

Ticker impact

$IONSBullishMedium confidence
Context

ARKG bought about $4.5 million of Ionis Pharmaceuticals.

Expected impact

Potential short‑term rally.

Evidence & confidence

Purchase size relative to float is notable.

$VCYTBullishMedium confidence
Context

ARKG bought nearly $3 million of Veracyte.

Expected impact

Likely modest upside.

Evidence & confidence

ETF buying adds credibility to the company's growth story.

$BEAMBullishMedium confidence
Context

ARKG bought roughly $2.6 million of Beam Therapeutics.

Expected impact

Short‑term price lift expected.

Evidence & confidence

Fund purchase size is material for a small‑cap biotech.

$SCTXBullishMedium confidence
Context

ARKG bought about $1.9 million of Scribe Therapeutics.

Expected impact

Potential upward pressure.

Evidence & confidence

Early‑stage company receiving significant ETF backing.

$TXGBearishLow confidence
Context

ARKG sold more than $2.5 million of 10x Genomics.

Expected impact

Minor downside pressure.

Evidence & confidence

Sale size is modest relative to market cap.

Market effects

Sector

Highlights continued investor interest in genomics and gene‑editing biotech.

Regional

U.S. biotech sector may see modest uplift.

Global

Signals broader confidence in precision‑medicine themes.

Counterpoint

What could challenge this read

Fund concentration could amplify downside if sector sentiment turns negative.

Key entities

  • Person
    Cathie Wood

    Founder of ARK Invest, driving the fund's investment decisions.

  • ETF
    ARK Genomic Revolution ETF

    Actively managed fund focusing on genomics and precision medicine.

Read at source← All news

Related articles

$BEAMMed

Philly scientists helped shape proposed FDA guidance that could accelerate gene therapies for rare diseases

The FDA proposed new guidelines to streamline approval for personalized gene therapies, enabling testing of a platform against multiple mutations. Scientists from Penn Medicine and Children's Hospital of Philadelphia developed a treatment for rare diseases, receiving a $39M federal award. The draft guidance allows for umbrella clinical trials, potentially attracting more investment in rare disease therapies. Beam Therapeutics is planning a clinical trial for a PKU gene-editing medicine.

inquirer.com
$SCTXMedAI 9/10

One Shot, Two Years of Lower Cholesterol: Scribe’s CRISPR Gene Therapy Begins Human Trials

Scribe Therapeutics (SCTX) presented data at AHA 2026 showing its gene therapy STX-1150 maintained LDL cholesterol control for two years in non-human primates. The therapy uses epigenetic gene silencing to target PCSK9. Separately, Scribe's STX-1200, a CRISPR-based LPA gene editor, showed durable Lp(a) reduction in preclinical models. Novartis' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, impacting competitors.

techtimes.com
$IONSLowAI 9/10

Pelacarsen no better than placebo in patients with high lipoprotein(a), heart disease

Ionis and Novartis' pelacarsen failed to reduce major adverse CV events in patients with high lipoprotein(a) and heart disease, according to the Lp(a)HORIZON trial. The drug did not outperform placebo in reducing CV events, with similar rates in both groups. The trial included 8,322 patients, with a median follow-up of 4.7 years. Despite the setback, experts urge continued research into lipoprotein(a) treatments.

healio.com
$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.

tradingview.com